Latest Csl News

CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.

Barramundi Limited (NZX:BRM) has reported the worst performance in its 20-year history, with a NZ$42.9 million net loss and a 17.0% fall in gross portfolio performance. The board is reviewing Fisher Funds’ management performance just weeks before its five-year agreement comes up for renewal.

Cadence Capital delivered a sharply stronger FY2026, with profit after tax rising to $33.4 million and its portfolio returning 20.1% against the All Ordinaries Accumulation Index. The listed investment company also moved decisively away from gold and resources, ending the year with $153.5 million in cash and a further 1.0 cent fully franked special dividend on the way.

Bellavista Resources is advancing a 15,000-metre drilling campaign and early development studies at Pickle Crow, while assay results have been pushed into October after Canadian laboratory delays. At Brumby, continuity drilling is complete and CSIRO column leach testwork is being prepared.

Cadence Opportunities Fund Limited (ASX:CDO) delivered a record $5.66 million after-tax profit and a 30.3% fund return in FY2026. The listed investment company is entering the new year with elevated cash, reduced gold exposure and a discounted share purchase plan underway.

Australian United Investment Company’s profit surged after its merger with Diversified United Investment, but the headline result was dominated by a one-off acquisition gain. Underlying profit rose 19.9%, while AUI expanded its portfolio to about A$3.1 billion and declared fully franked dividends totalling 28 cents per share.

Barramundi’s portfolio surged in August, delivering a 6.7% adjusted NAV return against a 1.9% benchmark gain. The recovery leaves the NZX-listed investment company trading at a 13.2% discount to its underlying portfolio value.

Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.

Australian Foundation Investment Company (ASX:AFI) reported a $293.5 million profit for FY26, holding dividends steady despite portfolio returns lagging the market. Leadership transitioned as Alison Gibson took the helm following Mark Freeman’s retirement.

Cadence Opportunities Fund delivered a standout FY26 with profit after tax soaring 279% to $5.66 million and a 30.3% fund return, prompting a fully franked final dividend and a special payout.

Cadence Capital Limited delivered a stellar 434% jump in profit after tax to $33.4 million for FY26, driven by a 313% revenue surge. The company declared a 3.0 cent fully franked final dividend plus a 1.0 cent special dividend, underpinning a strong yield amid active portfolio repositioning.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.